A community effort in SARS‐CoV‐2 drug discovery

Archive ouverte

Schimunek, Johannes | Seidl, Philipp | Elez, Katarina | Hempel, Tim | Le, Tuan | Noé, Frank | Olsson, Simon | Raich, Lluís | Winter, Robin | Gokcan, Hatice | Gusev, Filipp | Gutkin, Evgeny | Isayev, Olexandr | Kurnikova, Maria | Narangoda, Chamali | Zubatyuk, Roman | Bosko, Ivan | Furs, Konstantin | Karpenko, Anna | Kornoushenko, Yury | Shuldau, Mikita | Yushkevich, Artsemi | Benabderrahmane, Mohammed | Bousquet-Melou, Patrick | Bureau, Ronan | Charton, Beatrice | Cirou, Bertrand | Gil, Gérard | Allen, William | Sirimulla, Suman | Watowich, Stanley | Antonopoulos, Nick | Epitropakis, Nikolaos | Krasoulis, Agamemnon | Pitsikalis, Vassilis | Theodorakis, Stavros | Kozlovskii, Igor | Maliutin, Anton | Medvedev, Alexander | Popov, Petr | Zaretckii, Mark | Eghbal-Zadeh, Hamid | Halmich, Christina | Hochreiter, Sepp | Mayr, Andreas | Ruch, Peter | Widrich, Michael | Berenger, Francois | Kumar, Ashutosh | Yamanishi, Yoshihiro | Zhang, Kam | Bengio, Emmanuel | Bengio, Yoshua | Jain, Moksh | Korablyov, Maksym | Liu, Cheng-Hao | Gilles, Marcous | Glaab, Enrico | Barnsley, Kelly | Iyengar, Suhasini | Ondrechen, Mary Jo | Haupt, V. Joachim | Kaiser, Florian | Schroeder, Michael | Pugliese, Luisa | Albani, Simone | Athanasiou, Christina | Beccari, Andrea | Carloni, Paolo | d'Arrigo, Giulia | Gianquinto, Eleonora | Goßen, Jonas | Hanke, Anton | Joseph, Benjamin | Kokh, Daria | Kovachka, Sandra | Manelfi, Candida | Mukherjee, Goutam | Muñiz-Chicharro, Abraham | Musiani, Francesco | Nunes-Alves, Ariane | Paiardi, Giulia | Rossetti, Giulia | Sadiq, S. Kashif | Spyrakis, Francesca | Talarico, Carmine | Tsengenes, Alexandros | Wade, Rebecca | Copeland, Conner | Gaiser, Jeremiah | Olson, Daniel | Roy, Amitava | Venkatraman, Vishwesh | Wheeler, Travis | Arthanari, Haribabu | Blaschitz, Klara | Cespugli, Marco | Durmaz, Vedat | Fackeldey, Konstantin | Fischer, Patrick | Gorgulla, Christoph | Gruber, Christian | Gruber, Karl | Hetmann, Michael | Kinney, Jamie | Das, Krishna | Pandita, Shreya | Singh, Amit | Steinkellner, Georg | Tesseyre, Guilhem | Wagner, Gerhard | Wang, Zi-Fu | Yust, Ryan | Druzhilovskiy, Dmitry | Filimonov, Dmitry | Pogodin, Pavel | Poroikov, Vladimir | Rudik, Anastassia | Stolbov, Leonid | Veselovsky, Alexander | de Rosa, Maria | Simone, Giada De | Gulotta, Maria | Lombino, Jessica | Mekni, Nedra | Perricone, Ugo | Casini, Arturo | Embree, Amanda | Gordon, D. Benjamin | Lei, David | Pratt, Katelin | Voigt, Christopher | Chen, Kuang-Yu | Jacob, Yves | Krischuns, Tim | Lafaye, Pierre | Zettor, Agnès | Rodríguez, M. Luis | White, Kris | Fearon, Daren | von Delft, Frank | Walsh, Martin | Horvath, Dragos | Brooks, Charles | Falsafi, Babak | Ford, Bryan | García-Sastre, Adolfo | Lee, Sang Yup | Naffakh, Nadia | Varnek, Alexandre | Klambauer, Guenter | Hermans, Thomas

Edité par CCSD ; Wiley-VCH -

International audience. The COVID‐19 pandemic continues to pose a substantial threat to human lives and is likely to do so for years to come. Despite the availability of vaccines, searching for efficient small‐molecule drugs that are widely available, including in low‐ and middle‐income countries, is an ongoing challenge. In this work, we report the results of an open science community effort, the “Billion molecules against Covid‐19 challenge”, to identify small‐molecule inhibitors against SARS‐CoV‐2 or relevant human receptors. Participating teams used a wide variety of computational methods to screen a minimum of 1 billion virtual molecules against 6 protein targets. Overall, 31 teams participated, and they suggested a total of 639,024 molecules, which were subsequently ranked to find ‘consensus compounds’. The organizing team coordinated with various contract research organizations (CROs) and collaborating institutions to synthesize and test 878 compounds for biological activity against proteases (Nsp5, Nsp3, TMPRSS2), nucleocapsid N, RdRP (only the Nsp12 domain), and (alpha) spike protein S. Overall, 27 compounds with weak inhibition/binding were experimentally identified by binding‐, cleavage‐, and/or viral suppression assays and are presented here. Open science approaches such as the one presented here contribute to the knowledge base of future drug discovery efforts in finding better SARS‐CoV‐2 treatments.

Suggestions

Du même auteur

Noncovalent Inhibitors of SARS-CoV-2 Main Protease: A Rescaffolding Attempt

Archive ouverte | Krischuns, Tim | CCSD

International audience. Out of the results of the sole large-scale screening for inhibitors of SARS-CoV-1 main protease reported in 2013, attempts to improve the identified 3-pyridyl-bearing hits have been conducted...

The need to implement FAIR principles in biomolecular simulations

Archive ouverte | Amaro, Rommie | CCSD

International audience. This letter illustrates the opinion of the molecular dynamics (MD) community on the need to adopt a new FAIR paradigm for the use of molecular simulations. It highlights the necessity of a co...

Design and synthesis of naturally-inspired SARS-CoV-2 inhibitors

Archive ouverte | Hassan, Haitham | CCSD

International audience. A naturally inspired chemical library of 25 molecules was synthesised guided by 3-D dimensionality and naturalproduct likeness factors to explore a new chemical space. The synthesised chemica...

Chargement des enrichissements...